[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$6share](/topic/$6share) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "Key moves from todays filings: -Spin-off: $JNJ to separate its Orthopaedics business into standalone DePuy Synthes within 18-24 months -Merger Arb: $RYN/$PCH agree to $8.2B all-stock merger XXXXXX Rayonier shares per PCH share (8.25% premium) -Merger Arb: $AKRO to be acquired by Novo Nordisk for $54/share plus $6/share CVR (total $5.2B) -Allegation: $JEF addressed fraud allegations related to Point Bonita Capitals exposure in First Brands Group -CEO Change: $VMC names Ronnie A. Pruitt next CEO; $PRIM appoints Koti Vadlamudi as CEO Full details in thread below" [X Link](https://x.com/catalyst8kio/status/1978390416111345805) [@catalyst8kio](/creator/x/catalyst8kio) 2025-10-15T09:20Z XX followers, XX engagements "$ETNB competitor developing a MASH treatment $AKRO was just acquired by $NVO. Big pharma is clearly betting heavily on these drugs. Theres also an interesting CVR component attached to the AKRO deal. The offer is for $54/share in cash + $6/share in CVR and the stock currently trades at $54.08/share. The CVR payout is tied to the cirrhosis indication approval as well but with much stronger upside than in the case of ETNB. I havent looked into this in detail yet but its worth checking out" [X Link](https://x.com/InvestSpecial/status/1976643630484869147) [@InvestSpecial](/creator/x/InvestSpecial) 2025-10-10T13:39Z 31K followers, 5818 engagements "Novo Nordisk to acquire Akero Therapeutics $AKRO for up to $5.2B. Structured with an upfront payment of $4.7B in cash ($54/share) a XX% premium to $AKRO 30-day VWAP. Also includes a $6/share CVR dependent upon full U.S. regulatory approval of efruxifermin (EFX) by June XX 2031" [X Link](https://x.com/ForFairnessSake/status/1976391702702416151) [@ForFairnessSake](/creator/x/ForFairnessSake) 2025-10-09T20:57Z XX followers, XX engagements "ðĒM&A News: Novo Nordisk to acquire Akero Therapeutics for up to $5.2B ðĻ ð° $54/share cash + $6/share CVR tied to FDA approval of efruxifermin for MASH cirrhosis ð XX% premium to Akeros pre-deal price 𧎠Adds Phase X FGF21 analog EFX to Novos metabolic portfolio ð Deal closes by YE 2025 pending approvals ðĪ Signals renewed M&A momentum in MASH/NASH. Validates FGF21 pathway.potential re-rating for peers like $VKTX $TERN See image for more details" [X Link](https://x.com/BiopharmIQ/status/1976303356961550704) [@BiopharmIQ](/creator/x/BiopharmIQ) 2025-10-09T15:06Z 27.4K followers, 16K engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Key moves from todays filings: -Spin-off: $JNJ to separate its Orthopaedics business into standalone DePuy Synthes within 18-24 months -Merger Arb: $RYN/$PCH agree to $8.2B all-stock merger XXXXXX Rayonier shares per PCH share (8.25% premium) -Merger Arb: $AKRO to be acquired by Novo Nordisk for $54/share plus $6/share CVR (total $5.2B) -Allegation: $JEF addressed fraud allegations related to Point Bonita Capitals exposure in First Brands Group -CEO Change: $VMC names Ronnie A. Pruitt next CEO; $PRIM appoints Koti Vadlamudi as CEO Full details in thread below"
X Link @catalyst8kio 2025-10-15T09:20Z XX followers, XX engagements
"$ETNB competitor developing a MASH treatment $AKRO was just acquired by $NVO. Big pharma is clearly betting heavily on these drugs. Theres also an interesting CVR component attached to the AKRO deal. The offer is for $54/share in cash + $6/share in CVR and the stock currently trades at $54.08/share. The CVR payout is tied to the cirrhosis indication approval as well but with much stronger upside than in the case of ETNB. I havent looked into this in detail yet but its worth checking out"
X Link @InvestSpecial 2025-10-10T13:39Z 31K followers, 5818 engagements
"Novo Nordisk to acquire Akero Therapeutics $AKRO for up to $5.2B. Structured with an upfront payment of $4.7B in cash ($54/share) a XX% premium to $AKRO 30-day VWAP. Also includes a $6/share CVR dependent upon full U.S. regulatory approval of efruxifermin (EFX) by June XX 2031"
X Link @ForFairnessSake 2025-10-09T20:57Z XX followers, XX engagements
"ðĒM&A News: Novo Nordisk to acquire Akero Therapeutics for up to $5.2B ðĻ ð° $54/share cash + $6/share CVR tied to FDA approval of efruxifermin for MASH cirrhosis ð XX% premium to Akeros pre-deal price 𧎠Adds Phase X FGF21 analog EFX to Novos metabolic portfolio ð Deal closes by YE 2025 pending approvals ðĪ Signals renewed M&A momentum in MASH/NASH. Validates FGF21 pathway.potential re-rating for peers like $VKTX $TERN See image for more details"
X Link @BiopharmIQ 2025-10-09T15:06Z 27.4K followers, 16K engagements
/topic/$6share/posts